# Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

> **NCT03721341** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **David Palma** · enrollment: 204 (actual)

## Conditions studied

- Metastatic Tumors

## Interventions

- **RADIATION:** Palliative Radiation
- **DRUG:** Chemotherapy
- **DRUG:** Immunotherapy
- **DRUG:** Hormones
- **OTHER:** Observation
- **RADIATION:** Stereotactic Ablative Radiotherapy

## Key facts

- **NCT ID:** NCT03721341
- **Lead sponsor:** David Palma
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-22
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721341, "Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT03721341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*